

DESCRIPTION

Species Reactivity	Human
Specificity	Detects human VSIG8 in direct ELISAs.
Source	Monoclonal Mouse IgG ₁ Clone # 961840
Purification	Protein A or G purified from hybridoma culture supernatant
Immunogen	Human embryonic kidney cell line HEK293-derived transfected with human VSIG8 Met1-Gly263 Accession # Q5VU13
Conjugate	Alexa Fluor 700 Excitation Wavelength: 675-700 nm Emission Wavelength: 723 nm
Formulation	Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide *Contains <0.1% Sodium Azide, which is not hazardous at this concentration according to GHS classifications. Refer to the Safety Data Sheet (SDS) for additional information and handling instructions.

APPLICATIONS

Please Note: Optimal dilutions should be determined by each laboratory for each application. [General Protocols](#) are available in the Technical Information section on our website.

ELISA Optimal dilution of this antibody should be experimentally determined.

PREPARATION AND STORAGE

Shipping	The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied

BACKGROUND

VSIG8 (V-set and immunoglobulin domain containing 8), also known as C1orf204, is an approximately 45 kDa type I transmembrane protein of the B7 family within the Ig superfamily. Mature human VSIG8 consists of a 242 amino acid (aa) extracellular domain (ECD) containing two V-type Ig-like domains, a 21 aa transmembrane domain, and a 130 aa cytoplasmic domain. Within the ECD, human VSIG8 shares 88% and 89% aa identity with mouse and rat VSIG8, respectively. Alternative splicing generates a long isoform of human VSIG8 with a substitution in the cytoplasmic juxtamembrane region and a 124 aa extension at the C-terminus. VSIG8 was identified from proteomic analysis of human hair shafts (1, 2). It is expressed in the hair follicle and shaft, superficial layers of the nail matrix, and superficial layers of oral epithelium (3). R&D Systems in-house testing indicates that VSIG8 inhibits the production of IL-2 by activated T cells.

PRODUCT SPECIFIC NOTICES

This product is provided under an agreement between Life Technologies Corporation and R&D Systems, Inc, and the manufacture, use, sale or import of this product is subject to one or more US patents and corresponding non-US equivalents, owned by Life Technologies Corporation and its affiliates. The purchase of this product conveys to the buyer the non-transferable right to use the purchased amount of the product and components of the product only in research conducted by the buyer (whether the buyer is an academic or for-profit entity). The sale of this product is expressly conditioned on the buyer not using the product or its components (1) in manufacturing; (2) to provide a service, information, or data to an unaffiliated third party for payment; (3) for therapeutic, diagnostic or prophylactic purposes; (4) to resell, sell, or otherwise transfer this product or its components to any third party, or for any other commercial purpose. Life Technologies Corporation will not assert a claim against the buyer of the infringement of the above patents based on the manufacture, use or sale of a commercial product developed in research by the buyer in which this product or its components was employed, provided that neither this product nor any of its components was used in the manufacture of such product. For information on purchasing a license to this product for purposes other than research, contact Life Technologies Corporation, Cell Analysis Business Unit, Business Development, 29851 Willow Creek Road, Eugene, OR 97402, Tel: (541) 465-8300. Fax: (541) 335-0354.